Adaptive Biotechnologies
ADPT | NASDAQ
$27.87
-$1.17 (-4.03%)
At close: Nov 16, 2026, 4:00 PM ET
$27.87
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Adaptive Biotechnologies Company Profile
Company profile explainedCompany Profile
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
Key Executives
| Name | Position |
|---|---|
| Chad Robins | Co-Founder, Chief Executive Officer & Chairman |
| Francis T. Lo | Chief People Officer |
| Julie Rubinstein | President & Chief Operating Officer |
| Kyle Piskel | Vice President, Chief Financial Officer & Principal Accounting Officer |
| Christopher Carlson | Founder |
| Clarice McCauley | Head of Legal, Corporate Secretary, VP & Chief Compliance Officer |
| Karina Calzadilla | VP of Investor Relations and FP&A |
| Mary Pat Lancelotta | Senior Vice President, Global Market & Business Development |
| Sharon Benzeno | Chief Commercial Officer of Immune Medicine |
| Susan Bobulsky | Chief Commercial Officer of MRD |
Adaptive Biotechnologies
| Country | United States |
| IPO Date | Jun 27, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 624 |
| CEO | Chad Robins |
Contact Details
1165 Eastlake Avenue East Seattle,
Washington 98109 United States
Stock Details
| Ticker Symbol | ADPT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001478320 |
| CUSIP Number | 00650F109 |
| ISIN Number | US00650F1093 |
| SIC Code | 2836 |
Recent News
- 6 days ago / globenewswire.comAdaptive Biotechnologies to Participate in Upcoming Investor Conferences
- 6 days ago / zacks.comAdaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run?
- 12 days ago / seekingalpha.comAdaptive Biotechnologies Corporation (ADPT) Q3 2026 Earnings Call Transcript
- 12 days ago / zacks.comAdaptive Biotechnologies (ADPT) Q3 Earnings and Revenues Top Estimates
- 12 days ago / zacks.comAdaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- 12 days ago / marketbeat.comAdaptive Biotechnologies Q3 Earnings Call Highlights
- 21 days ago / seekingalpha.comAdaptive Biotechnologies: Getting Paid Every Step Of The Way To A Myeloma Cure
- 1 month ago / globenewswire.comAdaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026
- 1 month ago / gurufocus.comAdaptive Biotechnologies Corp (ADPT) Stock Down 3.5% but Still Overvalued -- GF Score: 68/100
- 2 months ago / globenewswire.comAdaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
Add to Watchlist
Select watchlists to add or remove ADPT